Growth attenuation therapy for children with severe physical and cognitive disability: Practice and perspectives of New Zealand paediatricians

J Paediatr Child Health. 2017 Dec;53(12):1180-1185. doi: 10.1111/jpc.13629. Epub 2017 Jul 3.

Abstract

Aim: There are currently no clinical guidelines concerning the administration of growth attenuation therapy (GAT) for children (regardless of gender) with both severe physical and cognitive disability in New Zealand (NZ). This survey aimed to explore the attitudes of paediatricians towards GAT and the frequency of requests and initiation of GAT in NZ.

Methods: An online survey of paediatricians in NZ was undertaken. Questions covered both clinical experience with GAT and attitudes towards it.

Results: Overall, the response rate was 55% (173/317) with 162 complete responses; 25% of respondents (41/166) reported enquiries about GAT. Five had personally prescribed GAT; in total, six NZ children have undergone GAT. A total of 77% of respondents either believed GAT is appropriate or were neutral on the subject. The majority of responders (59%) believed ethical approval should be obtained as part of preparation for GAT.

Conclusions: This is the first study to investigate attitudes and practices of NZ paediatricians regarding GAT for severely disabled children. Results indicate a range of views but suggest that family requests for GAT do occur and that the majority of paediatricians are not opposed to GAT in the appropriate ethical and clinical context. The development of practice guidelines for GAT may lead to a more informed decision-making process about GAT for families and paediatricians.

Keywords: children; disability; ethics; growth attenuation therapy.

MeSH terms

  • Child
  • Child, Preschool
  • Disabled Children / statistics & numerical data*
  • Female
  • Growth Inhibitors / therapeutic use*
  • Health Knowledge, Attitudes, Practice*
  • Humans
  • Male
  • New Zealand
  • Pediatricians / statistics & numerical data
  • Surveys and Questionnaires

Substances

  • Growth Inhibitors